Scientific Program

Updated as of May 16, 2022
It is based on the local time of Seoul, Korea. (UTC+9)

Thursday, June 16

Plenary Lecture 1

Date & Time Thursday, June 16, 10:40-11:20 Place Room A
  1. Dynamic changes of tumor infiltrating immune cells during immunotherapies
    Zemin Zhang (Biomedical Pioneering Innovation Center, Peking University, China)

Plenary Lecture 2

Date & Time Thursday, June 16, 11:20-12:00 Place Room A
  1. The barriers in clinical application of cancer precision medicine: Lessons from K-MASTER project
    Yeul Hong Kim (Korea University College of Medicine, Korea)

AOS Session 1

Session Title Recent updates in liver cancer
Date & Time Thursday, June 16, 13:25-15:05 Place Room A
  1. 1)Molecular carcinogenesis of cholangiocarcinoma
    Bin Tean Teh (National Cancer Center Singapore, Singapore)
  1. 2)Liver transplantation for HCC
    Kwang-Woong Lee (Seoul National University College of Medicine, Korea)
  1. 3)Recent updates in radiotherapy for hepatocellular carcinoma
    Angela Giselvania (Dr Cipto Mangunkusumo Hospital, Indonesia)
  1. 4)Emerging therapeutic options for HCC and cholangiocarcinoma
    Tae-Yong Kim (Seoul National University College of Medicine, Korea)

Symposium 01

Session Title Risk factors of cancer in Asia
Date & Time Thursday, June 16, 08:40-10:20 Place Room A
  1. 1)Human carcinogens in Asia: Information from the WHO classification of tumours
    Ian A Cree (World Health Organization, France)
  1. 2)Diet and cancer risk in Asia
    Jung Eun Lee (Seoul National University, Korea)
  1. 3)Modifiable and unmodifiable risk factors for cancer in Asia
    Manami Inoue (National Cancer Center, Japan)
  1. 4)Current Status and prevention of Occupational carcinogen exposure in Asia
    Inah Kim (Hanyang University College of Medicine, Korea)

Symposium 02

Session Title Cancer drug discovery from proteomics
Date & Time Thursday, June 16, 08:40-10:20 Place Room B
  1. 1)Activation mechanism of toll-like receptors
    Jie-Oh Lee (POSTECH, Korea)
  1. 2)Proteomics and application in Translational research
    Kyunggon Kim (University of Ulsan College of Medicine, Korea)
  1. 3)Combining discovery and targeted proteomics reveals a prognostic signature in oral cancer
    Adriana Franco Paes Leme (Brazilian Biosciences National Laboratory, Brazil)
  1. 4)Machine learning powered next-generation proteomics
    Lennart Martens (VIB and Ghent University, Belgium)

Symposium 03

Session Title AI in cancer genomics
Date & Time Thursday, June 16, 08:40-10:20 Place Room D
  1. 1)Network-based machine-learning to predict drug efficacy in cancer patients
    Sanguk Kim (Pohang University of Science and Technology, Korea)
  1. 2)Applications of machine learning in cancer immunotherapy
    Jung Kyoon Choi (KAIST, Korea)
  1. 3)Harnessing synthetic lethality to advance precision cancer medicine
    Joo Sang Lee (Sungkyunkwan University School of Medicine, Korea)
  1. 4)Exploring phenotype patterns of breast cancer within somatic mutations
    Hiroshi Mamitsuka (Kyoto University, Japan)

Symposium 04

Session Title Cancer predisposition syndrome
Date & Time Thursday, June 16, 08:40-10:20 Place Room E
  1. 1)Diagnosis of hereditary breast-ovarian cancer syndrome
    Jong-Won Kim (Sungkyunkwan University School of Medicine, Korea)
  1. 2)Surveillance in Li Fraumeni syndrome
    Mandy Ballinger (Garvan Institute of Medical Research, Australia)
  1. 3)Screening and management of individuals with neurofibromatosis 1
    Hyery Kim (University of Ulsan College of Medicine, Korea)
  1. 4)Future genetic medicine based on HBOC phenotype and genotype
    Reiko Yoshida (Showa University, Japan)

Symposium 05

Session Title Digital pathology for cancer diagnosis
Date & Time Thursday, June 16, 13:25-15:05 Place Room D
  1. 1)Integrating digital pathology into clinical practice
    Chan Kwon Jung (The Catholic University of Korea College of Medicine, Korea)
  1. 2)Digitized network for pathologic diagnosis in Japan
    Junya Fukuoka (Nagasaki University Graduate School of Biomedical Sciences, Japan)
  1. 3)Digital pathology project in Korea
    Keetaek Jang (Sungkyunkwan University School of Medicine, Korea)
  1. 4)Application of deep learning for cancer histological grading
    Mattias Rantalainen (Karolinska Institute, Sweden)

Symposium 06

Session Title Liquid biopsy in precision oncology
Date & Time Thursday, June 16, 13:25-15:05 Place Room E
  1. 1)Review of ctDNA analysis in patients with cancer
    Jason D. Merker (University of North Carolina School of Medicine, USA)
  1. 2)Monitoring minimal residual disease based on ctDNA in breast cancer
    Wonshik Han (Seoul National University College of Medicine, Korea)
  1. 3)Liquid biopsy for advanced NSCLC - IASLC consensus statement
    Daniel Tan Shao Weng (National Cancer Center Singapore, Singapore)
  1. Q&A Discussion

Symposium 07

Session Title Image-guided cancer surgery
Date & Time Thursday, June 16, 15:25-17:05 Place Room B
  1. 1)Efficacy of 3-dimensional printed breast surgical guide in breast conserving surgery
    Beom Seok Ko (University of Ulsan College of Medicine, Korea)
  1. 2)Cutting edge technology of intraoperative near-infrared fluorescence Image during thoracic tumor surgery
    Hyun Koo Kim (Korea University College of Medicine, Korea)
  1. 3)Application of fluorescence imaging to liver cancer surgery
    Xiaoying Wang (Liver Cancer Institute, Zhongshan Hospital, Fudan University, China)
  1. 4)Utility of intraoperative fluorescence imaging in gynecologic cancer surgery
    Mikel Gorostidi Pulgar (Donostia Hospital, Spain)

Symposium 08

Session Title Novel techniques in radiation oncology
Date & Time Thursday, June 16, 15:25-17:05 Place Room D
  1. 1)Appllication of artificial intelligence in radiation oncology
    Steve B. Jiang (University of Texas Southwestern Medical Center, USA)
  1. 2)Autosegmentation of target volume and normal organ delineation
    Yongjin(Norman) Zhu (Manteia Medical Technologies Co., China)
  1. 3)Ultra-high dose rate (FLASH) radiotherapy
    Hiromitsu Iwata (Nagoya Proton Therapy Center, Japan)
  1. 4)Proton minibeam technique for clinical application
    Young Kyung Lim (National Cancer Center, Korea)

Symposium 09

Session Title Monitoring minimal residual disease
Date & Time Thursday, June 16, 15:25-17:05 Place Room E
  1. 1)MRD in hematologic oncology
    Anthony S. Stein (City of Hope, USA)
  1. 2)The role of Flow-, PCR- and NGS-based MRD in hematologic malignancies
    Myungshin Kim (The Catholic University of Korea College of Medicine, Korea)
  1. 3)Analysis of cfDNA in colon cancer
    Claus Lindbjerg Andersen (Aarhus University Hospital, Denmark)
  1. 4)Liquid Bx for MRD of breast cancer
    Han-Byoel Lee (Seoul National University College of Medicine, Korea)

Special Symposium 1

Session Title Practice changing clinical study results in Asia (I) - Gastric Cancer
Date & Time Thursday, June 16, 15:25-17:05 Place Room A
  1. 1)Epidemiology of gastric cancer in Asia
    Manami Inoue (National Cancer Center, Japan)
  1. 2)Surgical oncology in Japan
    Yasuhiro Kodera (Nagoya University Graduate School of Medicine, Japan)
  1. 3)Surgical oncology in China
    Jiafu Ji (Peking University Cancer Hospital & Institute, China)
  1. 4)Medical oncology in the East
    Do-Youn Oh (Seoul National University College of Medicine, Korea)
  1. 5)Medical oncology in the West
    Yelena Y. Janjigian (Memorial Sloan Kettering Cancer Center, USA)

Joint Symposium 1
KCA & Korean Association of Immunologists

Session Title Cancer immunology
Date & Time Thursday, June 16, 13:25-15:05 Place Room B
  1. 1)Trajectory of immune evolution in hepatocellular carcinoma
    Valerie Chew (SingHealth-DukeNUS, Singapore)
  1. 2)Modulation of tumor immune responses by dead cell-derived molecules
    Hideyuki Yanai (The University of Tokyo, Japan)
  1. 3)Towards next generation T cell engineering for Cancer Immunotherapy
    Chan Hyuk Kim (KAIST, Korea)
  1. 4)Disparate differentiation between naive and memory CD8 T cells during persistent antigenic stimulation
    Se Jin Im (Sungkyunkwan University School of Medicine, Korea)

Satellite Symposium 1 (MSD)

Date & Time Thursday, June 16, 12:10-12:50 Place Room A
  1. CLEAR (KN581) - A new approval of novel combination, pembrolizumab plus lenvatinib in advanced RCC
    In-Ho Kim (The Catholic University of Korea College of Medicine, Korea)

Satellite Symposium 2 (Amgen)

Date & Time Thursday, June 16, 12:10-12:50 Place Room D
  1. Sotorasib, the first target therapy for kras g12c mt. NSCLC
    Benjamin Solomon (Peter MacCallum Cancer Centre, Australia)

Oral Presentation 1

Date & Time Thursday, June 16, 08:40-10:20 Place Room C
  1. 1)Laparoscopic PPG versus DG for middle third EGC; Final result of multicenter RCT (KLASS-04)
    Hyuk-Joon Lee (Seoul National University Hospital, Korea)
  1. 2)The anatomical configuration of the splenic artery influences suprapancreatic lymph node dissection in laparoscopic gastrectomy: analysis using a 3D volume rendering program
    Chunchao Zhu (Shanghai Jiao Tong University, China)
  1. 3)Significance of mid-radiotherapy 18F-fluorodeoxyglucose positron emission tomography/computed tomography in esophageal cancer
    Byung Min Lee (The Catholic University of Korea Uljeongbu St. Mary's Hospital, Korea)
  1. 4)Thoracic cavity-to-cage ratio is a predictor of technical difficulties in minimally invasive esophagectomy
    Tomoki Abe (Graduate School of Medicine, Kobe University, Japan)
  1. 5)Association between G8 score and overall survival in the patients with esophageal cancer treated with definitive chemoradiotherapy
    Ryo Narukami (Kyoto University, Japan)
  1. 6)Chemotherapy-induced reprogramming of cancer-associated fibroblasts promotes gastric cancer progression and resistance to chemotherapy
    Inhye Ham (Ajou University Hospital, Korea)
  1. 7)Prediction model for screening patients at risk of malnutrition after gastric cancer surgery
    Ji-Hyeon Park (Gachon University Gil Medical Center, Korea)
  1. 8)Comprehensive analysis of alternative splicing in gastric cancer identifies epithelial-mesenchymal transition subtypes associated with survival
    Yun-Suhk Suh (Seoul National University Bundang Hospital, Korea)
  1. 9)Genomic and evolutionary characteristics of gastric cancer by metastatic routes
    Yoon Young Choi (CHA University School of Medicine, Korea)
  1. 10)Activation of JAK-STAT1 signaling pathway is an early response to helicobacter pylori infection and contributes to immune escape and gastric carcinogenesis
    Xue Li (Peking University Cancer Hospital, China)

Oral Presentation 2

Date & Time Thursday, June 16, 13:25-15:05 Place Room C
  1. 1)Secondary malignancies in cancer survivors and the susceptibility to hereditary multiple cancer syndrome: A Korean nationwide population-based study
    Yoon Young Choi (CHA University School of Medicine, Korea)
  1. 2)Universal genetic testing identifies more hereditary cancer syndrome patients than guideline directed targeted testing: A multi-center prospective study
    May Chow (Invitae, Singapore)
  1. 3)Associations between patterns of physical activity and incidence of cancer among obese adults in Korean: Results from health examinees-G study
    Jaesung Choi (Seoul National University Medical Research Center, Korea)
  1. 4)Risk of cancer development and mortality in women with prediabetes and diabetes: A population-based cohort study
    Thi Xuan Mai Tran (Hanyang University College of Medicine, Korea)
  1. 5)Effect of Helicobacter pylori eradication on blood metabolite fingerprints and their interactions on the progression of gastric lesions
    Wen-Qing Li (Peking University Cancer Hospital, China)
  1. 6)Integration of DNA methylation data of TCGA cancer and KoGES normal samples: Survival rate and chronic disease by clustering pattern
    Jeong-An Gim (Korea University Guro Hospital, Korea)
  1. 7)Exposure to high serum levels of IL-6 is associated with increased lifetime risk of cancer
    Yoo Hyung Kim (Seoul National University Hospital, Korea)
  1. 8)Healthcare utilization of cancer patients during the COVID-19 pandemic
    Seung Hee Seo (Seoul National University Hospital, Korea)

Oral Presentation 3

Date & Time Thursday, June 16, 15:25-17:05 Place Room C
  1. 1)Long-term survival analysis from colorectal cancer associated with Microsatellite instability and tumor-infiltrating lymphocytes and Crohn's-like lymphoid reaction
    Chul Seung Lee (The Catholic University of Korea Seoul St. Mary's Hospital, Korea)
  1. 2)Inhibition of 15-prostaglandin dehydrogenase(15-PGDH) enhances colon cancer metastasis by upregulation of Epithelial to mesenchymal transition(EMT)-associated genes via increasing PGE2 level
    Ki Beom Bae (Inje University Busan Paik Hospital, Korea)
  1. 3)A microRNA panel in Normal tissue Adjacent to the Tumor (NAT) is a predictive biomarker for colorectal cancer recurrence
    Lui Ng (The University of Hong Kong, Hong Kong, China)
  1. 4)Circulating tumor DNA mutations in progressive gastrointestinal stromal tumors identify drug resistance biomarkers and uncover potential therapeutic strategies
    Tun Kiat Ko (National Cancer Centre Singapore, Singapore)
  1. 5)Post-operative genomic/epigenomic signatures of circulating tumor DNA and recurrence in colorectal cancer: COSMOS-CRC-01
    Nobuhisa Matsuhashi (Gifu University Hospital, Japan)
  1. 6)Association of preoperative dietary habits and exercise with postoperative complications in patients who underwent elective surgery for colorectal cancer: A prospective cohort study
    Hyo Jun Kim (Seoul National University Hospital, Korea)
  1. 7)The watch‑and‑wait strategy versus surgical resection for rectal cancer patients with a good response (≤ycT2) after neoadjuvant chemoradiotherapy
    Chungyeop Lee (Pohang Naval Hospital, Korea)
  1. 8)Comparison of chemoradiation therapy vs. adjuvant chemotherapy alone in patients with extremely low rectal cancer requiring abdominoperineal resection
    Nahyeon Park (Soon Chun Hyang University Bucheon Hospital, Korea)
  1. 9)The role of adjuvant radiotherapy in node-negative parotid gland cancer
    Jung Bin Park (Seoul National University Hospital, Korea)

Friday, June 17

Plenary Lecture 3

Date & Time Friday, June 17, 10:40-11:20 Place Room A
  1. Pancreas Cancer - Improving outcomes through molecular diagnostics and therapeutics
    Jeffrey A. Drebin (Memorial Sloan Kettering Cancer Center, USA)

Jin-Pok Kim Memorial Lecture

Date & Time Friday, June 17, 11:20-12:00 Place Room A
  1. Clonal evolution in normal tissues
    Seishi Ogawa (Kyoto University Graduate School of Medicine, Japan)

AOS Session 2

Session Title Future leadership of AOS
Date & Time Friday, June 17, 13:25-15:05 Place Room A
  1. 1)Yeul Hong Kim (Korea University Medical College, Korea)
  1. 2)Sanjeev Misra (All India Institute of Medical Sciences, Jodhpur, India)
  1. 3)Ying Wang (China Anti-Cancer Association, China)
  1. 4)Kazuhiro Yoshida (Gifu University, Graduate School of Medicine, Japan)
  1. Panelists
    Agus Rizal Ardy Hariandy Hamid (Indonesian Urology Oncology Society, Indonesia)
    Hsuen Elaine Lim (National Cancer Centre Singapore, Singapore)
    Ekaphop Sirachainan (Ramathibodi Hospital, Mahidol University, Thailand)
    Dang Huy Quoc Thinh (Ho Chi Minh City Oncology Hospital, Vietnam)
    Zeba Aziz (Hameed Latif Hospital, Pakistan)
    Gloria R. Cristal-Luna (St. Luke’s Medical Center Quezon City, Philippines)

Symposium 10

Session Title Survivorship in cancer care
Date & Time Friday, June 17, 08:40-10:20 Place Room A
  1. 1)Unique needs and concerns of childhood cancer survivors
    Yasushi Ishida (Ehime Prefectural Central Hospital, Japan)
  1. 2)Development of survivorship care coordination model:Experiences in Japan
    Miyako Tsuchiya (Musashino University, Japan)
  1. 3)Integrating psycho-oncology to improve mental health for cancer survivors
    Seockhoon Chung (University of Ulsan College of Medicine, Korea)
  1. 4)The effect of exercise on the QoL and survival in cancer survivors
    Justin Y. Jeon (Yonsei University, Korea)

Symposium 11

Session Title Novel targeted therapy and resistance
Date & Time Friday, June 17, 08:40-10:20 Place Room B
  1. 1)Novel targeted therapy and resistance in EGFR-mutant lung cancer
    Ji-Youn Han (National Cancer Center, Korea)
  1. 2)HER2-targeted therapy
    Shaheenah Dawood (Mohammed Bin Rashid University of Medicine and Health Sciences, UAE)
  1. 3)Anti-angiogenetic therapy
    Masafumi Ikeda (National Cancer Center Hospital East, Japan)
  1. 4)Potential role of targeted agents in IO-refractory gastric cancer
    Jeeyun Lee (Sungkyunkwan University School of Medicine, Korea)

Symposium 12

Session Title Current consensus of treatment for oligometastasis
Date & Time Friday, June 17, 08:40-10:20 Place Room D
  1. 1)Oligometastases: What have we learned?
    David Anthony Palma (London Health Sciences Centre, Canada)
  1. 2)Korean radiation oncologists' perspective
    Chai Hong Rim (Korea University College of Medicine, Korea)
  1. 3)Korean medical oncologists' perspective: What is the definition of ‘Oligo’?
    Dae Ho Lee (University of Ulsan College of Medicine, Korea)
  1. 4)Management of oligometastasis from colorectal cancer
    Jong-Hoon Lee (The Catholic University of Korea College of Medicine, Korea)
  1. 5)Locally aggressive hypofractionated RT(SBRT) for Oligometastatic NSCLC
    Hak Choy (University of Texas Southwestern Medical Center, USA)

Symposium 13

Session Title Novel immunotherapy and resistance
Date & Time Friday, June 17, 13:25-15:05 Place Room B
  1. 1)Immunologic resistance mechanisms of cancer immunotherapy
    Eui-Cheol Shin (KAIST, Korea)
  1. 2)Immunotherapy resistance and its overcoming strategy in lung cancer
    Se-Hoon Lee (Sungkyunkwan University School of Medicine, Korea)
  1. 3)Immunotherapy resistance and its overcoming strategy in gastric cancer
    Narikazu Boku (IMSUT Hospital, Institute of Medical Science, University of Tokyo, Japan)
  1. 4)Immunotherapy combination therapy for immune checkpoint inhibitor-resistant cancer
    Hussein A. Tawbi (University of Texas MD Anderson Cancer Center, USA)

Symposium 14

Session Title DNA damage response in cancer
Date & Time Friday, June 17, 15:25-17:05 Place Room B
  1. 1)Targeting the DNA damage response pathway in advanced cancers
    David SP Tan (National University of Singapore, Singapore)
  1. 2)Mechanisms of resistance to PARP inhibitors in advanced cancers
    Kyung-Hun Lee (Seoul National University College of Medicine, Korea)
  1. 3)PARP inhibition in future
    Nicola Jane Curtin (Newcastle University, UK)
  1. Q&A Discussion

Symposium 15

Session Title 암관련학회협의체 심포지엄: National Cancer Guideline
Date & Time Friday, June 17, 15:25-17:05 Place Room C
  1. 1)국가암진료 가이드라인 사업 소개
    김열 (국립암센터)
  1. 2)국가암진료 가이드라인 개발 방법론
    김수영 (한림의대)
  1. 3)사업비 개괄 및 객관적 집행 방안
    곽호신 (국립암센터)
  1. 4)참여학회의 기대와 보완점 - 대한대장항문학회
    엄준원 (고려의대)
  1. 5)참여학회의 기대와 보완점 - 대한갑상선학회
    이은경 (국립암센터)
  1. 패널토론
    한상균 (보건복지부), 김시영 (건강보험심사평가원), 김현정 (고려대 근거중심의학연구소), 김병기 (성균관의대)

Symposium 16

Session Title Palliative care in Asian countries
Date & Time Friday, June 17, 15:25-17:05 Place Room E
  1. 1)Past, present, future of palliative care in Japan
    Yusuke Hiratsuka (Takeda General Hospital, Japan)
  1. 2)Past, present, future of palliative care in Taiwan
    Shao-Yi Cheng (College of Medicine and Hospital, National Taiwan University, Taiwan)
  1. 3)Recent efforts to expand horizons of palliative care in Korea
    Yu Jung Kim (Seoul National University College of Medicine, Korea)
  1. 4)Life-sustaining treatment states in Korean cancer patients after enforcement of act on decisions on life-sustaining treatment
    Jung Hye Kwon (Chungnam National University College of Medicine, Korea)

Special Symposium 2

Session Title Practice changing clinical study results in Asia (II) – Lung Cancer
Date & Time Friday, June 17, 15:25-17:05 Place Room A
  1. 1)Lung cancer screening
    Pan-Chyr Yang (National Taiwan University, Taiwan)
  1. 2)Anatomical extent of lung parenchyma in the radical resection for lung cancer: Does segmentectomy surrogate lobectomy for small-sized, peripheral lung cancer?
    Hisao Asamura (Keio University School of Medicine, Japan)
  1. 3)Radiation treatment for metastatic EGFR-mutant non-small cell lung cancer
    Zhengfei Zhu (Fudan University Shanghai Cancer Center, China)
  1. 4)Practice changing clinical study results in Asia – Medical treatment for lung cancer
    Myung-Ju Ahn (Sungkyunkwan University School of Medicine, Korea)

Joint Symposium 2
KCA & Korea Genome Organization

Session Title Deeper understanding of cancer genomes
Date & Time Friday, June 17, 13:25-15:05 Place Room D
  1. 1)Landscape and function of multiple mutations within individual oncogenes
    Keisuke Kataoka (Keio University School of Medicine, Japan)
  1. 2)Extrachromosomal DNA in multiple cancers
    Hoon Kim (Sungkyunkwan University, Korea)
  1. 3)Recent insights from single-cell-omics studies in colorectal cancer
    Iain Tan (National Cancer Centre Singapore, Singapore)
  1. 4)Mutation pairs with evolutionary dependency in cancer genomes
    Tae-Min Kim (The Catholic University of Korea College of Medicine, Korea)

Joint Symposium 3
KCA & Korean Society for Neuro-Oncology

Session Title Biology and treatment of CNS metastases
Date & Time Friday, June 17, 13:25-15:05 Place Room E
  1. 1)Molecular biology of CNS metastases
    Ho-Shin Gwak (National Cancer Center, Korea)
  1. 2)Targeted therapy for advanced cancer with CNS metastases
    Hye Ryun Kim (Yonsei University College of Medicine, Korea)
  1. 3)Local treatment for CNS metastases in the targeted therapy era
    Young Zoon Kim (Sungkyunkwan University School of Medicine, Korea)
  1. 4)RANO response criteria for brain and leptomeningeal metastases
    Seung Hong Choi (Seoul National University College of Medicine, Korea)

Joint Symposium 4
KCA & Korean Society of Gynecologic Oncology

Session Title Recent strategies for treating cervical cancer
Date & Time Friday, June 17, 15:25-17:05 Place Room D
  1. 1)Evolution of cervical cancer treatment with the emergence of immune checkpoint inhibitors
    Masahiro Kagabu (Iwate Medical University, Japan)
  1. 2)2020 WHO classification of cervical adenocarcinoma
    Cheol Lee (Seoul National University College of Medicine, Korea)
  1. 3)Recent advance of radiotherapy for cervical cancer
    Sezin Yuce Sari (Hacettepe University Medical School, Turkey)
  1. 4)DNA vaccine as a novel treatment for cervical cancer in future
    Youn Jin Choi (The Catholic University of Korea College of Medicine, Korea)

Satellite Symposium 3 (Servier)

Date & Time Friday, June 17, 11:20-11:40 Place Room D
  1. Liposomal irinotecan and innovative drug delivery system in pancreatic cancer
    Kyu-Pyo Kim (University of Ulsan College of Medicine, Korea)

Satellite Symposium 4 (Pfizer)

Date & Time Friday, June 17, 12:10-12:50 Place Room A
  1. Maximizing clinical benefit with CDK4/6 inhibitors: Long-term efficacy & safety of palbociclib
    Kyung-Hun Lee (Seoul National University College of Medicine, Korea)

Satellite Symposium 5 (AstraZeneca)

Date & Time Friday, June 17, 12:10-12:50 Place Room D
  1. Today & Tomorrow of EGFRm NSCLC: From early to advanced stage
    Sun Min Lim (Yonsei University College of Medicine, Korea)

Outstanding Abstract Session

Date & Time Friday, June 17, 08:40-09:40 Place Room E
  1. 1)Adoptive transfer of T cells targeting shared p53 neoantigens to treat human solid cancers
    Sanghyun Kim (National Cancer Institute, USA)
  1. 2)Oncologic outcome between abdominoperineal resection and sphincter preservation surgery for low rectal cancer; A long-term survival analysis of prospective, multicenter, cohort ASPIRE study
    Hong-min Ahn (Seoul National University Bundang Hospital, Korea)
  1. 3)Immunogenic responses of ChAdOx1nCoV-19 and CoronaVac vaccines in cancer patients receiving chemotherapy and non-chemotherapy treatment
    Chayanee Samdaengpan (Chulabhorn Royal Academy, Thailand)

Oral Presentation 4

Date & Time Friday, June 17, 08:40-10:20 Place Room C
  1. 1)Depleting tumor infiltrating myeloid cells to enhance bispecific antibody-driven T cell infiltration and anti-tumor immune response
    Jeong A Park (Inha University Hospital, Korea)
  1. 2)Anti-mesothelin human CAR-T cells producing IL-7 and CCL19 enhance antitumor efficacy against solid cancer in orthotopic and PDX mouse models
    Shunsuke Goto (Kyushu University, Graduate School of Medical Sciences, Japan)
  1. 3)Therapeutic potential of anti-vascular endothelial growth factor receptor 2 therapy for M2 tumor-associated macrophages in colorectal cancer
    Koji Kono (Fukushima Medical University, Japan)
  1. 4)Highly selective inhibitor for AXL overcomes stroma-induced resistance to chemotherapeutic agents through downregulation of ABCG1 in gastric cancer
    Taehoon Kim (Ajou University School of Medicine, Korea)
  1. 5)Targeting metabolic variance and plasticity as a novel therapeutic strategy for triple-negative breast cancer
    Jiyoung Lee (George Washington University, USA)
  1. 6)Established patient-derived organoids using ascites fluid or pleural effusion in cancer patients
    Yebeen Yu (National Cancer Center, Korea)
  1. 7)Disc-type 3D in vitro cancer modeling system for spatiotemporal visualization of cell-cell interaction
    Haruko Takahashi (Hiroshima University, Japan)
  1. 8)High-throughput functional evaluation of human cancer-associated mutations using base editors
    Seungho Lee (Yonsei University College of Medicine, Korea)

Oral Presentation 5

Date & Time Friday, June 17, 13:25-15:05 Place Room C
  1. 1)Novel NSDHL inhibitor (Compound 9) induces cytotoxic activity and G0/G1 arrest in breast cancer cells
    So-Hyun Yoon (Seoul National University, Korea)
  1. 2)Prediction of platinum-based chemotherapy resistance for epithelial ovarian cancer
    Heekyoung Song (The Catholic University of Korea Incheon St. Mary's Hospital, Korea)
  1. 3)The clinical impact of age-specific distribution combination patterns of cytology & high-risk HPV status in the background of cervical intraepithelial neoplasia grade 3 or greater
    Mie Sakai (Shiga General Hospital, Japan)
  1. 4)Homologous recombination deficiency in pancreas ductal adenocarcinoma and treatment outcome: A multicenter real-world experience
    Yung-Yeh Su (National Health Research Institutes, Taiwan)
  1. 5)An integrative single-cell transcriptome analysis reveals transitional cancer cell state associated with poor prognosis in pancreatic cancer
    Galam Leem (Severance Hospital, Korea)
  1. 6)Spatial transcriptomics reveals perineural invasion signature showing clinically relevant therapeutic resistance in the patient with advanced gallbladder cancer
    Sung Hwan Lee (CHA University School of Medicine, Korea)
  1. 7)CADM1 and SPC25 gene mutations in lung cancer patients with idiopathic pulmonary fibrosis
    Aya Fukuizumi (Nippon Medical School, Japan)
  1. 8)Patient-derived cells (PDCs) recapitulate tumor heterogeneity (TH) to target therapy in advanced lung cancer patients
    Youngjoo Lee (National Cancer Center, Korea)
  1. 9)Efficacy of immune checkpoint inhibitors and concordance between intra/extracranial response in non-small cell lung cancer patients with brain metastasis
    Sora Kang (Chungnam National University Hospital, Korea)
  1. 10)Overall survival in patients with EGFR T790M-positive advanced non-small cell lung cancer treated with lazertinib: Results from the phase I/II study
    Ji-Youn Han (National Cancer Center, Korea)

Saturday, June 18

Symposium 17

Session Title New frontiers in cancer drug development
Date & Time Saturday, June 18, 08:40-10:20 Place Room A
  1. 1)Modifiers of cancer immunity
    Junho Chung (Seoul National University College of Medicine, Korea)
  1. 2)Novel discovery of antibody-drug conjugates for advanced cancers
    Kaku Saito (Daiichi Sankyo, Inc, USA)
  1. 3)Mapping the degradable kinome using PROTACs
    Taebo Sim (Yonsei University College of Medicine, Korea)
  1. Q&A Discussion

Symposium 18

Session Title Tissue-agnostic anticancer drugs: A paradigm shift in leveraging cancer biology for precision medicine
Date & Time Saturday, June 18, 10:40-12:20 Place Room A
  1. 1)Update of NTRK inhibitors for NTRK fusion-positive tumors
    David S. Hong (The University of Texas MD Anderson Cancer Center, USA)
  1. 2)Pembrolizumab for MSI-H or dMMR tumors
    Do-Youn Oh (Seoul National University College of Medicine, Korea)
  1. 3)HER2 targeted agents in breast, gut, and beyond
    Kyung Hae Jung (University of Ulsan College of Medicine, Korea)
  1. 4)Novel clinical trial designs for tissue-agnostic drug development
    Jee Hyun Kim (Seoul National University College of Medicine, Korea)

Joint Symposium 5
KCA & Asian Oncology Nursing Society

Session Title Collaborative modalities for better cancer care
Date & Time Saturday, June 18, 08:40-10:20 Place Room B
  1. 1)Addressing cancer care disparities through collaboration: opportunities and future directions
    Winnie K.W.So (The Chinese University of Hong Kong, Hong Kong, China)
  1. 2)Care of cancer survivors in a multi-disciplinary clinic
    Janette Vardy (University of Sydney, Australia)
  1. 3)Networking development and information sharing among Asian oncology nurses
    Eunyoung Suh (Seoul National University College of Nursing, Korea)
  1. 4)Integration of supportive palliative care through the overall trajectory of cancer care
    Su-Jin Koh (University of Ulsan College of Medicine, Korea)

Joint Symposium 6
KCA & Korean GIST Study Group

Session Title Novel therapies in GIST
Date & Time Saturday, June 18, 10:40-12:20 Place Room B
  1. 1)Endoscopic resection of gastric GIST
    Hwoon-Yong Jung (University of Ulsan College of Medicine, Korea)
  1. 2)Advance in surgical resection of GIST
    Toshiro Nishida (National Cancer Center Hospital, Japan)
  1. 3)Chemotherapy
    Li-Tzong Chen (Kaohsiung Medical University, Taiwan)
  1. 4)Molecular pathology of GISTs for precision medicine
    Hye Seung Lee (Seoul National University College of Medicine, Korea)

Joint Symposium 7
KCA & Korean Spine Oncology Research Society

Session Title Management of spinal bone metastases
Date & Time Saturday, June 18, 10:40-12:20 Place Room C
  1. 1)Algorithm based approach for spinal metastasis
    Fon-Yih Tsuang (National Taiwan University Hospital, Taiwan)
  1. 2)Total en block spondylectomy and immunotherapy for spinal metastasis
    Kota Watanabe (Keio University School of Medicine, Japan)
  1. 3)Total en block spondylectomy- Setting resection margin based on tumor location
    Arjun Sahgal (Odette Cancer Centre, University of Toronto, Canada)
  1. 4)Role of chemotherapy for spinal bone metastasis
    Tae-Yong Kim (Seoul National University College of Medicine, Korea)